Karyopharm Therapeutics (KPTI) Receivables - Net (2019 - 2025)
Historic Receivables - Net for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $26.2 million.
- Karyopharm Therapeutics' Receivables - Net fell 1491.26% to $26.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.2 million, marking a year-over-year decrease of 1491.26%. This contributed to the annual value of $26.2 million for FY2025, which is 1491.26% down from last year.
- Per Karyopharm Therapeutics' latest filing, its Receivables - Net stood at $26.2 million for Q4 2025, which was down 1491.26% from $31.9 million recorded in Q3 2025.
- In the past 5 years, Karyopharm Therapeutics' Receivables - Net ranged from a high of $47.1 million in Q4 2022 and a low of $17.8 million during Q1 2021
- For the 5-year period, Karyopharm Therapeutics' Receivables - Net averaged around $29.5 million, with its median value being $30.9 million (2024).
- In the last 5 years, Karyopharm Therapeutics' Receivables - Net skyrocketed by 10929.9% in 2022 and then crashed by 4273.88% in 2023.
- Karyopharm Therapeutics' Receivables - Net (Quarter) stood at $22.5 million in 2021, then skyrocketed by 109.3% to $47.1 million in 2022, then crashed by 42.74% to $27.0 million in 2023, then rose by 14.11% to $30.8 million in 2024, then fell by 14.91% to $26.2 million in 2025.
- Its last three reported values are $26.2 million in Q4 2025, $31.9 million for Q3 2025, and $32.9 million during Q2 2025.